-
Droxidopa
- indication:For treatment of neurogenic orthostatic hypotension associated with various disorders including Multiple System Atrophy, Familial Amyloid Polyneuropathy, hemodialysis induced hypotension and Parkinson's Disease. Also investigated for use/treatment in neurologic disorders, nephropathy, blood (blood forming organ disorders, unspecified), and dizzy/fainting spells.
- pharmacologypharmacology:
- mechanism: Droxidopa crosses the blood-brain barrier where it is converted to norepinephrine. Increased levels of norepinephrine in the central nervous system (CNS) may be beneficial to patients in a wide range of indications.
- toxicity:
- absorprion: Oral bioavailability is 90%.
- halflife: 2-3 hours
- roouteelimination:
- volumedistribution:
- clearance: